What is already known about this subject• Rivaroxaban is a novel anticoagulant with
predictable, dose‐proportional pharmacokinetics and pharmacodynamics in healthy …

Rivaroxaban (BAY 59‐7939) is an oral, direct Factor Xa inhibitor in advanced clinical
development for the prevention and treatment of thromboembolic disorders. This was a …

Background: There is a clinical need for novel oral anticoagulants with predictable
pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Prior to the commencement of this
study, it was already known that rivaroxaban is partially cleared via the kidneys and an …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Rivaroxaban is an oral, direct Factor
Xa inhibitor in advanced clinical development for the prevention and treatment of …

Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose …

Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial
infarction, and stroke often result in long‐term disability and/or mortality. The anticoagulants …

Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially
attractive alternative to vitamin K antagonists. Rivaroxaban is being investigated for the …

There are several novel anticoagulants in development that target factor Xa (FXa)-the pivotal
point of the coagulation cascade. One promising agent is rivaroxaban (a highly selective …

Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the
blood coagulation pathway leading to thrombin generation and clot formation. It is selective …